Leadership
|
Irene M. Ghobrial, MD
Professor of Medicine, Harvard Medical School Attending Physician, Medical Oncology Director, Clinical Investigator Research Program Director, Michele & Stephen Kirsch Laboratory Co-Director, Center for the Prevention of Progression of Blood Cancers (CPOP) Dana-Farber Cancer Institute education Hematology, Mayo Clinic Graduate Medical Education, 2004 Oncology, Mayo Clinic Graduate Medical Education, 2004 Internal Medicine, Sinai-Grace Hospital of Detroit, 2001 MD, Cairo University School of Medicine, 1995 |
Dr. Ghobrial is a clinician and scientist who specializes in the field of Multiple Myeloma (MM) and precursor conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM).
Dr. Ghobrial completed her M.D. at Cairo University, Residency in Internal Medicine at Wayne State University, and Hematology/Oncology Fellowship at Mayo Clinic. She is currently a Professor of Medicine and the Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber Cancer Institute, Harvard Medical School. She is the Director of the Clinical Investigator Research Program, Director of Translational Research in the Department of Multiple Myeloma, Director of the Center for Prevention of Progression diseases (CPOP), and co-leader of the Lymphoma and Myeloma Program at Dana-Farber.
Dr. Ghobrial's laboratory research is focused on understanding how early precursor conditions like MGUS and SMM progress to overt MM. We examine the genetic, epigenetic, and immune alterations that contribute to disease progression to active Multiple Myeloma. We work to understand the biological changes that occur during progression and develop therapeutic strategies to stop progression in its tracks. In addition, her research has been translated to innovative investigator-initiated clinical trials. She has led over 15 phase I and II clinical trials, and studies on the bone marrow and immune microenvironments are currently being translated into immunotherapy trials in high-risk precursor patients.
She is the co-leader of the Center for Prevention of Progression of Blood Cancers (CPOP), where patients with precursor conditions such as MGUS, early Myelodysplastic Syndrome (MDS), and early Chronic Lymphocytic Leukemia (CLL) are monitored prospectively for clonal evolution during disease progression. CPOP coordinates clinical trials and research efforts for patients with these conditions to develop therapeutic agents that can prevent or delay disease progression in these early malignant conditions. The PROMISE study, which is screening healthy people who may be at risk for precursor conditions and MM, and the PCROWD study, a tissue bank study collecting samples from patients with precursor conditions, are part of this effort.
Dr. Ghobrial completed her M.D. at Cairo University, Residency in Internal Medicine at Wayne State University, and Hematology/Oncology Fellowship at Mayo Clinic. She is currently a Professor of Medicine and the Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber Cancer Institute, Harvard Medical School. She is the Director of the Clinical Investigator Research Program, Director of Translational Research in the Department of Multiple Myeloma, Director of the Center for Prevention of Progression diseases (CPOP), and co-leader of the Lymphoma and Myeloma Program at Dana-Farber.
Dr. Ghobrial's laboratory research is focused on understanding how early precursor conditions like MGUS and SMM progress to overt MM. We examine the genetic, epigenetic, and immune alterations that contribute to disease progression to active Multiple Myeloma. We work to understand the biological changes that occur during progression and develop therapeutic strategies to stop progression in its tracks. In addition, her research has been translated to innovative investigator-initiated clinical trials. She has led over 15 phase I and II clinical trials, and studies on the bone marrow and immune microenvironments are currently being translated into immunotherapy trials in high-risk precursor patients.
She is the co-leader of the Center for Prevention of Progression of Blood Cancers (CPOP), where patients with precursor conditions such as MGUS, early Myelodysplastic Syndrome (MDS), and early Chronic Lymphocytic Leukemia (CLL) are monitored prospectively for clonal evolution during disease progression. CPOP coordinates clinical trials and research efforts for patients with these conditions to develop therapeutic agents that can prevent or delay disease progression in these early malignant conditions. The PROMISE study, which is screening healthy people who may be at risk for precursor conditions and MM, and the PCROWD study, a tissue bank study collecting samples from patients with precursor conditions, are part of this effort.